ライフサイエンスコーパス: bladder tumor

1 a molecular clock to determine the age of a bladder tumor.

2 storing IFN sensitivity in a subset of human bladder tumors.

3 nrichment with APOBEC-signature mutations in bladder tumors.

4 aled in cells derived from the most advanced bladder tumors.

5 recursor of low-grade, superficial papillary bladder tumors.

6 lasia and superficial papillary non-invasive bladder tumors.

7 e INK4A gene occur frequently in superficial bladder tumors.

8 retinoic acid and etretinate) in superficial bladder tumors.

9 so may be a late event in the development of bladder tumors.

10 10 bladder cancer cell lines and 14 primary bladder tumors.

11 ct GLI1 were found in resected human primary bladder tumors.

12 63 acting as an oncogene in certain invasive bladder tumors.

13 re that is strongly associated with invasive bladder tumors.

14 as done to determine mRNA expression from 96 bladder tumors.

15 ethylation at certain genes in both lung and bladder tumors.

16 tegies have been studied in the treatment of bladder tumors.

17 te cancer xenografts and established UM-UC-3 bladder tumors.

18 ethylation and loss of expression in primary bladder tumors.

19 against targets differentially expressed in bladder tumors.

20 of aggressive clinical behavior in advanced bladder tumors.

21 fied based on its overexpression in invasive bladder tumors.

22 in induction of apoptosis preferentially in bladder tumors.

23 atients initially diagnosed with early-stage bladder tumors (14 with nonprogressive disease and 15 wi

24 ed to analyze the transcript profiles of 105 bladder tumors: 33 superficial, 72 invasive lesions, and

25 TXAS is overexpressed in common forms of bladder tumors: 69 of 97 (71.1%) transitional cell carci

26 ly and more extensively in UTT (94%) than in bladder tumors (76%; P < .0001).

27 hance bladder surveillance and transurethral bladder tumor, a purpose-specific robotic system for LES

28 complete genome analysis, we sequenced five bladder tumors accrued from patients with muscle-invasiv

29 ceived no LT, transurethral resection of the bladder tumor alone, or < 50 Gy of radiation therapy del

30 s is both necessary and sufficient to induce bladder tumors along a low-grade, noninvasive papillary

31 In the present study RB negative bladder tumors also exhibited strong nuclear p16 stainin

32 A transurethral resection of the bladder tumor and biopsy identified transitional cell ca

33 we have carried out mutation analysis of 62 bladder tumors and 33 bladder tumor-derived cell lines t

34 f nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on th

35 Kalpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladde

36 ir combined expression was shown to stratify bladder tumors and define squamous differentiation.

37 cificity and sensitivity in the detection of bladder tumors and extravesical disease relative standar

38 was also hypermethylated in 11 of 16 primary bladder tumors and in 3 of 4 primary colon tumors when c

39 ) biopsies that represented both superficial bladder tumors and invasive bladder cancers.

40 ease stratification and outcome prognosis in bladder tumors and noninvasive diagnosis in urinary samp

41 cle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of my

42 a better understanding of LOI, we studied 41 bladder tumors and their adjacent normal bladder mucosa.

43 78 are down-regulated in prostate, colon and bladder tumors, and human cancer cell lines.

44 capable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a p

45 bitor of angiogenesis, in the development of bladder tumor angiogenesis.

46 RECENT FINDINGS: Strategies including bladder tumor antigen assay, NMP22, ImmunoCyt, and UroVy

47 Bladder tumors are characterized by markedly increased a

48 Cell-free extracts of muscle-invasive bladder tumors are defective in nonhomologous end-joinin

49 d that growth rates for ectopic melanoma and bladder tumors are increased in Adora2a(-/-) mice within

50 ty that recurrences of low-grade superficial bladder tumors are related to the continuing presence of

51 upports the hypothesis that male rat urinary bladder tumors arise through urinary bladder calculi for

52 The bladder tumor-associated hyaluronidase activity is disti

53 on increased incidences of male rat urinary bladder tumors at high exposure levels and on female mou

54 Gene profiling successfully classified bladder tumors based on their progression and clinical o

55 ortant in understanding pathways critical to bladder tumor biology.

56 e variants by screening genomic DNA of human bladder tumors, bladder cancer cell lines, and normal bl

57 orphism at codon 88 was noted in one primary bladder tumor, but no other abnormalities were found, su

58 logically valid approach in patients without bladder tumors, but is limited by technical consideratio

59 ene in several lethal tumor types, including bladder tumors, but its role as a pathogenic driver has

60 p53exons 4-9 were amplified from 146 bladder tumors by PCR, screened by single-strand conform

61 in the development of low-grade superficial bladder tumors by using a heterotopically transplanted r

62 intravesical administration of these agents, bladder tumors can be detected using fluorescence cystos

63 es unique patterns of gene expression during bladder tumor cell differentiation.

64 n human fibroblast cells (LD419) and a human bladder tumor cell line (T24).

65 e mismatch repair to the mutant extract, the bladder tumor cell line is likely to be defective in an

66 12-myristate 13-acetate treatment of the T24 bladder tumor cell line resulted in a time- and dose-dep

67 Analysis of the T24 bladder tumor cell line reveals a functional autocrine l

68 G1 cell cycle arrest by 5-Aza-CdR in the T24 bladder tumor cell line were also heritable after prolon

69 Migrating NBT-II cells (a rat bladder tumor cell line) were microinjected with the cag

70 -hexanoyl-D-sphingosine, in an Rb-null human bladder tumor cell line, 5637, as well as in retrovirall

71 Experiments on the human bladder tumor cell line, HT1376, showed that exisulind i

72 In bladder tumor cell lines derived from aggressive carcino

73 Here we find that 11 out of the 14 bladder tumor cell lines examined express one or more VE

74 Analysis of a panel of 33 bladder tumor cell lines revealed regions of contiguous

75 nvolved in the survival and proliferation of bladder tumor cells as well as other tumor cell types.

76 in A was evident in its inhibitory growth of bladder tumor cells in a nude mice model (57% of inhibit

77 ntly higher urine TRAIL levels, which killed bladder tumor cells in vitro versus nonresponders.

78 Comparative transcriptomic analysis of bladder tumor cells isolated from PDXs indicates unique

79 t coculture of murine bone marrow cells with bladder tumor cells promoted strong expression of PD-L1

80 d the fate of DBCCR1-expressing cells, human bladder tumor cells were transiently transfected with an

81 ive phenotype was similarly observed in 253J bladder tumor cells, in which Sod expression resulted in

82 ChoKalpha is constitutively altered in human bladder tumor cells.

83 e inhibitors (HDACi) against TRAIL-resistant bladder tumor cells.

84 MT) that combines transurethral resection of bladder tumor, chemotherapy for radiation sensitization,

85 tumor grade and overall patient survival in bladder tumors contained in tissue microarrays.

86 utation analysis of 62 bladder tumors and 33 bladder tumor-derived cell lines to establish the freque

87 The bladder tumor-derived hyaluronidase present in CM and pa

88 The identification of bladder tumor-derived hyaluronidase should help in eluci

89 nd in the partially purified preparations of bladder tumor-derived hyaluronidase.

90 In this study, we characterized the bladder tumor-derived hyaluronidase.

91 stoscopy is a promising technique for use in bladder tumor detection of lesions larger than 5 mm.

92 Mice were implanted with human 253J-BV bladder tumors (EGF+) or human SN12-PM6 renal tumors (EG

93 enetic alterations seen in 178 patients with bladder tumors (either muscle-invasive or non-muscle-inv

94 is resistant to progression to full-fledged bladder tumors even in the absence of Ink4a/Arf.

95 The fact that phenotypically different bladder tumors exhibit different patterns of cell cycle

96 ASS1 expression status in bladder tumors from 183 Caucasian and 295 Asian patients

97 However, compared to other tumors, bladder tumors from both exposed and unexposed individua

98 which it is possible to differentiate human bladder tumors from normal bladder epithelial cells.

99 frequency and pattern of p53 mutations in 34 bladder tumors from people with high-level occupational

100 tional exposure to arylamines to those in 30 bladder tumors from people without such exposure.

101 murine VEGFR-2, on orthotopic human 253J-BV bladder tumors growing in nude mice.

102 activity of other dietary components against bladder tumor growth and metastasis.

103 Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 ce

104 ata suggest that soy isoflavones can inhibit bladder tumor growth through a combination of direct eff

105 , HYAL-v1 expression may negatively regulate bladder tumor growth, infiltration, and angiogenesis.

106 curring in SV40T transgenic mice) to promote bladder tumor growth.

107 A second group (two bladder tumors) had no chromothripsis, and a simpler gen

108 ermine the aggressive clinical course of the bladder tumors harboring both p53 and pRB alterations.

109 meta-dataset of high-grade, muscle-invasive bladder tumors identified two intrinsic, molecular subse

110 istered orally) and against human breast and bladder tumors implanted in nude mice.

111 Clinically, ATDC was highly expressed in bladder tumors in a manner associated with invasive grow

112 arin was shown to produce a low incidence of bladder tumors in rats if administered in a two-generati

113 C-DIMs on bladder cancer cells in vitro and bladder tumors in vivo.

114 th the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogen

115 th factor receptor 3 (FGFR3) are frequent in bladder tumors, little information is available on their

116 cancer diagnosis and patient perspectives on bladder tumor markers.

117 Using a murine bladder tumor (MB49), which we show to express the male

118 f patients with NMIBC as a surrogate for the bladder tumor microenvironment.

119 This orthotopic human bladder tumor model also provides a clinically relevant

120 In this study, we report a transgenic mouse bladder tumor model upon induction of constitutively act

121 as investigated in vivo in an orthotopic rat bladder tumor model.

122 sease in murine B16/F10.9 melanoma and MBT-2 bladder tumor models.

123 at second look after transurethral resection bladder tumor, most still require radical cystectomy.

124 extended our methylation studies to resected bladder tumors (n = 128) and exfoliated cell samples (bl

125 samples (n = 25), and tissue microarrays of bladder tumors (n = 173).

126 tochemistry of tissue microarrays containing bladder tumors (n = 173).

127 hemistry using tissue microarrays of primary bladder tumors (n = 193 cases).

128 ive information by stratifying patients with bladder tumors (n = 37) based on their overall survival

129 cell lines (n = 28) and a cohort of primary bladder tumors (n = 98).

130 man tumor types (N = 1,630 samples) and with bladder tumors of different stages and grades (N = 144 s

131 ectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with long

132 gene expression profiles of 23 primary human bladder tumors of various stages and grades, and then we

133 e tumors with 82.2% accuracy, and stratified bladder tumors on the basis of clinical outcome.

134 lgorithms were used to classify and stratify bladder tumors on the basis of stage, node metastases, a

135 poptosis resistance and are overexpressed in bladder tumors, our data suggest that flavokawain A may

136 es involved and by the extent of the primary bladder tumor (p stage).

137 We also identified a bladder tumor patient carrying a germ-line mutation but

138 e found in the urine of normal and low-grade bladder tumor patients, the urine of high-grade bladder

139 risk population of patients with superficial bladder tumors, patients who have p53 nuclear overexpres

140 The detection of high-grade bladder tumors prior to invasion is crucial for a good p

141 ts cofactors, and have a pivotal role in the bladder tumor progression and the regulation of stem-lik

142 xpression of which inversely correlates with bladder tumor progression, demonstrating the usefulness

143 idase should help in elucidating its role in bladder tumor progression.

144 e, suggesting their potential involvement in bladder tumor progression.

145 ative advantage that plays a key role during bladder tumor progression.

146 Although 34 of 36 lines aligned to bladder tumors rather than other histologies, only 16 of

147 As over two-thirds of bladder tumors recur, vigilant surveillance is required.

148 skewing toward type 2 immunity, may predict bladder tumor recurrence and influence the mortality of

149 thout intravesical therapy), the superficial bladder tumor recurrence rate is 30% to 70% within 12 mo

150 Twenty-four patients (56%) developed bladder tumor recurrences from 5 to 96 months, which wer

151 treatment after transurethral resection of a bladder tumor, recurrences and progression remain a prob

152 %, or 81% reduction in the volume of 253J-BV bladder tumors, respectively, and 26%, 23%, or 51% reduc

153 ptional characterizations of mouse and human bladder tumors revealed a significant overlap and confir

154 r cancer cells, paired normal urothelium and bladder tumor samples (n = 25), and tissue microarrays o

155 ncreased PSCA mRNA expression in two sets of bladder tumor samples (n = 36, P = 0.0007 and n = 34, P

156 djuvant cisplatin-based chemotherapy primary bladder tumor samples from 30 muscle-invasive bladder ca

157 2 inhibitors are generating interest because bladder tumors seem to contain higher concentrations of

158 Invasive bladder tumors showed decreased nuclear myopodin express

159 e cancers, the majority of transitional cell bladder tumors showed Id1 protein expression in both tum

160 potential foundation for the development of bladder tumor-specific oncolytic viral therapies.

161 cal analysis was conducted in a series of 50 bladder tumor specimens, including 3 metastatic lymph no

162 une cells isolated from syngeneic mouse MB49 bladder tumors, spleens, and tumor-draining lymph nodes

163 affect prognosis independent of the primary bladder tumor stage.

164 However, during a search for candidate bladder tumor suppressor genes within the 9q34 region of

165 ising the possibility that this represents a bladder tumor suppressor.

166 at Cd24a-deficient male mice developed fewer bladder tumors than C57BL/6 control male mice.

167 he p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial pap

168 ring of CNAs defined two distinct classes of bladder tumors that differed in the degree of their CNA

169 ctive markers of the biological potential of bladder tumors that will enable identification of those

170 ns to treat low-grade, superficial papillary bladder tumors, the most common tumor in the urinary sys

171 agnosis and management of nonmuscle-invasive bladder tumors, the risk of both recurrence and progress

172 proximately 20% of patients with superficial bladder tumors, the tumors progress to invasive tumors a

173 For detection of bladder tumors, there was higher sensitivity for the UP

174 y remains the gold standard for diagnosis of bladder tumors, though fluorescent light and urinary bio

175 he HA levels are also elevated (3-5-fold) in bladder tumor tissues (P < 0.001).

176 In human bladder tumor tissues, the frequency and intensity of SP

177 are expressed in normal tissues/cells and G1 bladder tumor tissues.

178 ed-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy)

179 rrently performed transurethral resection of bladder tumor-TURP seems oncologically acceptable (in se

180 er profiles were characterized in 41 primary bladder tumors using array-based comparative genomic hyb

181 ression profiles of early-stage and advanced bladder tumors using cDNA microarrays containing 17,842

182 When comparing 15 primary bladder tumors versus a pool of four bladder cancer cell

183 der cancer model, curcumin alone reduced the bladder tumor volume, but a significantly greater reduct

184 An integrative analysis of 97 high-grade bladder tumors was conducted to identify actionable drug

185 Cyclin E protein expression analyzed in 265 bladder tumors was increased in aggressive tumors (P = 0

186 In both NMSC and bladder tumors we found a high prevalence of EMAST (75.4

187 Thus, bladder tumors were characterized by changes in miRNA ex

188 dies, 88% to 100% of mice bearing orthotopic bladder tumors were cured after four intravesical treatm

189 (100%) urine DNA samples from patients with bladder tumors were found to have 24 or more single-nucl

190 ATDC-driven bladder tumors were indistinguishable from human bladder

191 splicing variant, were found in the panel of bladder tumors while no mutation was observed in the ren

192 The majority of patients with invasive bladder tumors who achieve T0 status after neoadjuvant M

193 Patients with high-risk superficial bladder tumors who are treated successfully by a bladder

194 elation with overall survival in a subset of bladder tumors whose follow-up was available (n = 69).

195 for definitive local therapy of his primary bladder tumor with radical cystectomy or radiation.

196 he Drosophila patched gene (PTC), 20 primary bladder tumors with chromosome 9q LOH were screened for

197 tion of the second inactivation event in six bladder tumors with LOH of 10q implies that the PTEN/MMA

198 In a sample of bladder tumors with wild-type p53, elevated expression o

199 These bladder tumors, with impaired Notch signaling, also show

200 e-occurring low-grade, superficial papillary bladder tumors, without eliciting invasive carcinomas.

201 has been linked to the invasive phenotype in bladder tumors yet a primary role for N-cadherin in inva